Co-occurrences of mutation amplification, gain, deletions and high/low mRNA of HMGA2 with those of SMAD3, PJA1, and PJA2 in 348 HCC patients were significant with <0.001, 0.019, and 0.017 of P-values, respectively, while HMGA1 indicated high and low significant co-occurrences with PJA1 and PJA2, respectively (Figure 3A). This evidence concerns the gene SMAD3 and hepatocellular carcinoma.